论文部分内容阅读
目的：为提高乳腺癌患者内分泌治疗的敏感性，建立雌激素受体与靶基因结合活性的测定。方法：使用凝胶阻滞方法，用［γ－３２Ｐ］－ＡＴＰ标记雌激素效应元件（ＥＲＥ）作为探针检测 ８９例乳腺癌组织中 ＥＲ与靶基因 ＤＮＡ的结合活性。结果：８９例乳腺癌患者中５０例ＥＲ（＋）者中３５例ＥＲＥ（＋），占７０％；ＥＲ（＋）、ＰＲ（＋）的２２例中１８例ＥＲＥ（＋）；而ＥＲ（－）患者中有７例为ＥＲＥ（＋）占ＥＲ（－）患者的１８％。结论：依照ＥＲＥ的测定结果，结合ＥＲ，ＰＲ状态对临床乳腺癌的预后和抗激素治疗作出预测，并分为二大类：Ｉ类为ＥＲ（＋）、ＥＲＥ（＋）、ＰＲ（＋），这组患者预后较好，可优先考虑抗激素治疗 ； Ⅱ类为ＥＲ（－）、ＥＲＥ（－）、ＰＲ（－），抗激素治疗无效； ＥＲ（＋）、ＰＲ（－）组依据 ＥＲＥ（＋）归于Ⅰ类， ＥＲＥ（－）归于＋Ⅱ类；对于ＥＲ（－）、ＰＲ（＋）组ＥＲＥ（＋）为Ⅰ类，ＥＲＥ（－）为Ⅱ类。经过这样的分类可增加科学性，减少临床用药的盲目性。
Objective: To improve the sensitivity of endocrine therapy in breast cancer patients, to establish an estrogen receptor-target gene binding activity assay. METHODS: Gel-blocking method was used to detect the binding activity of ER to target gene DNA in 89 cases of breast cancer with [γ-32P]-ATP-labeled estrogen-responsive element (ERE) as a probe. RESULTS: Of the 89 breast cancer patients, 50 were ER (+), 35 were ERE (+), accounting for 70%, 22 were ER (+), PR (+), 18 were ERE (+), and ER ( - Among the patients, 7 were ERE (+) and 18% of ER (-) patients. Conclusions: According to the results of ERE determination, combined with ER and PR status, the prognosis of clinical breast cancer and anti-hormonal therapy are predicted and divided into two categories: Category I is ER(+), ERE(+), PR(+) This group of patients has a good prognosis and can be given priority to anti-hormone therapy; Type II is ER (-), ERE (-), PR (-), anti-hormonal therapy is ineffective; ER (+), PR (-) group based on ERE (+) is assigned to class I, and ERE(-) is assigned to class +II; for ER(-), PR(+) group, ERE(+) is class I, and ERE(-) is class II. After such classification can increase the scientific and reduce the blindness of clinical medication.